Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.3%

36 terminated/withdrawn out of 177 trials

Success Rate

75.5%

-11.0% vs industry average

Late-Stage Pipeline

2%

4 trials in Phase 3/4

Results Transparency

56%

62 of 111 completed trials have results

Key Signals

17 recruiting62 with results23 terminated13 withdrawn

Enrollment Performance

Analytics

Phase 2
73(44.8%)
Phase 1
47(28.8%)
N/A
38(23.3%)
Phase 3
4(2.5%)
Early Phase 1
1(0.6%)
163Total
Phase 2(73)
Phase 1(47)
N/A(38)
Phase 3(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (177)

Showing 20 of 177 trials
NCT05903092Phase 2Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Role: collaborator

NCT07218432Not ApplicableRecruiting

A Study of the TheraBionic P1 Device in Breast Cancer

Role: lead

NCT07118202Not ApplicableRecruiting

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

Role: lead

NCT03091257Phase 1Active Not Recruiting

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

NCT07436078Not ApplicableRecruiting

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

Role: lead

NCT03033914Phase 1Active Not Recruiting

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Role: collaborator

NCT05556473Phase 1Recruiting

F-Tryptophan PET/CT in Human Cancers

Role: lead

NCT01208662Phase 3Active Not Recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Role: collaborator

NCT07343297Not ApplicableNot Yet Recruiting

Ask Questions About Clinical Trials

Role: lead

NCT07227831Not ApplicableNot Yet Recruiting

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Role: lead

NCT05325281Phase 1Terminated

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Role: collaborator

NCT07130903Phase 2Recruiting

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Role: lead

NCT07098299Phase 1Recruiting

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

Role: lead

NCT03750981Not ApplicableRecruiting

C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)

Role: lead

NCT06576115Phase 2Recruiting

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Role: lead

NCT07222306Enrolling By Invitation

Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study

Role: collaborator

NCT03147885Phase 1Active Not Recruiting

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Role: lead

NCT04479267Phase 2Active Not Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Role: lead

NCT07095114Not ApplicableRecruiting

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Role: lead

NCT06908629Not ApplicableRecruiting

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

Role: lead